S
Si-Yang Liu
Researcher at South China University of Technology
Publications - 59
Citations - 1762
Si-Yang Liu is an academic researcher from South China University of Technology. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 13, co-authored 31 publications receiving 1003 citations. Previous affiliations of Si-Yang Liu include Peking Union Medical College & Guangdong General Hospital.
Papers
More filters
Journal ArticleDOI
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong,Zhong-Yi Dong,Wen-Zhao Zhong,Xu-Chao Zhang,Jian Su,Zhi Xie,Si-Yang Liu,Hai-Yan Tu,Hua-Jun Chen,Yue-Li Sun,Qing Zhou,Jin-Ji Yang,Xue-Ning Yang,Jia-Xin Lin,Hong-Hong Yan,Hao-Ran Zhai,Hao-Ran Zhai,Li-Xu Yan,Ri-Qiang Liao,Si-Pei Wu,Yi-Long Wu,Yi-Long Wu +21 more
TL;DR: Evidence is provided that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti-PD-1/PD-L1 immunotherapy.
Journal ArticleDOI
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong-Yi Dong,Jia-Tao Zhang,Si-Yang Liu,Jian Su,Chao Zhang,Zhi Xie,Qing Zhou,Hai-Yan Tu,Chong-Rui Xu,Li-Xu Yan,Y. Li,Wen-Zhao Zhong,Yi-Long Wu +12 more
TL;DR: Evidence is provided of a correlation between EGFR mutations and an uninflamed tumor microenvironment with immunological tolerance and weak immunogenicity, which caused an inferior response to PD-1 blockade in NSCLCs.
Journal ArticleDOI
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.
Shan Su,Zhong-Yi Dong,Zhi Xie,Li-Xu Yan,Y. Li,Jian Su,Si-Yang Liu,Kai Yin,Rui-lian Chen,Shu-Mei Huang,Zhi-Hong Chen,Jin-Ji Yang,Hai-Yan Tu,Qing Zhou,Wen-Zhao Zhong,Xu-Chao Zhang,Yi-Long Wu,Yi-Long Wu +17 more
TL;DR: The adverse effects of PD‐L1 expression on EGFR‐TKI efficacy, especially in NSCLC patients with de novo resistance, are revealed, indicating the reshaping of an inflamed immune phenotype characterized by PD‐ L1 and CD8 dual positivity and suggest potential therapeutic sensitivity to programmed death 1 blockade.
Journal ArticleDOI
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Hao Sun,Si-Yang Liu,Jia-Ying Zhou,Jin-Tian Xu,Huang-Kai Zhang,Hong-Hong Yan,Jiaojiao Huan,Pingping Dai,Chong-Rui Xu,Jian Su,Yanfang Guan,Xin Yi,Rong-Shan Yu,Wen-Zhao Zhong,Yi-Long Wu +14 more
TL;DR: This study demonstrated that not all TP53 mutations are equal in predicting efficacy in patients with LUAD treated with ICIs, and showed that TP53 missense and nonsense mutations were significantly different in associations with PD-L1 expression, IFN-γ signatures and TME composition.
Journal ArticleDOI
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
A. Li,Jin-Ji Yang,Xu-Chao Zhang,Zhou Zhang,Jian Su,Lan-Ying Gou,Yu Bai,Qing Zhou,Zhenfan Yang,Han Han-Zhang,Wen-Zhao Zhong,Shannon Chuai,Qi Zhang,Zhi Xie,Hong-Fei Gao,Hua-Jun Chen,Zhen Wang,Zheng Wang,Xue-Ning Yang,Bin-Chao Wang,Bin Gan,Zhi-Hong Chen,Ben-Yuan Jiang,Si-Pei Wu,Si-Yang Liu,Chong-Rui Xu,Yi-Long Wu +26 more
TL;DR: Insight is provided into the diversity of mechanisms underlying MET-TKI–induced resistance and the potential of sequential use ofMET-TKIs and it is discovered that EGFR amplification may act as an alternative MET- TKI resistance mechanism.